1) Sassa N : Retroperitoneal Tumors : Review of Diagnosis and Management. Int J Urol 27 : 1058-1070, 2020
2) WHO Classification of Tumours Editional Board : Soft Tissue and Bone Tumours, WHO Classification of Tumours, 5th Edition. International Agency for Research on Cancer, Lyon, 2020
3) Weiss SW, et al : Enzinger and Weiss's Soft Tissue Tumors, 7th Edition ; Elsevier, Amsterdam, 2020
4) Italiano A, et al : HMGA2 Is the Partner of MDM2 in Well-Differentiated and Dedifferentiated Liposarcomas Whereas CDK4 Belongs to a Distinct Inconsistent Amplicon. Int J Cancer 122 : 2233-2241, 2008
5) Weaver J, et al : Fluorescence in situ Hybridization for MDM2 Gene Amplification as a Diagnostic Tool in Lipomatous Neoplasms. Mod Pathol 21 : 943-949, 2008
6) Binh MBN, et al : MDM2 and CDK4 Immunostainings Are Useful Adjuncts in Diagnosing Well-Differentiated and Dedifferentiated Liposarcoma Subtypes : A Comparative Analysis of 559 Soft Tissue Neoplasms with Genetic Data. Am J Surg Pathol 29 : 1340-1347, 2005
7) Mariño-Enríquez A, et al : Dedifferentiated Liposarcoma with “Homologous” Lipoblastic (Pleomorphic Liposarcoma-Like) Differentiation : Clinicopathologic and Molecular Analysis of a Series Suggesting Revised Diagnostic Criteria. Am J Surg Pathol 34 : 1122-1131, 2010
8) Henricks WH, et al : Dedifferentiated Liposarcoma : A Clinicopathological Analysis of 155 Cases with a Proposal for an Expanded Definition of Dedifferentiation. Am J Surg Pathol 21 : 271-281, 1997
9) Wang W, et al : Targeting MDM2 for Novel Molecular Therapy : Beyond Oncology. Med Res Rev 40 : 856-880, 2020